GLP-1 diabetes and obesity drugs like semaglutide tied to 15% lower fracture risk and potential bone health benefits versus other weight-loss medications
CHICAGO — GLP-1 diabetes and obesity drugs like semaglutide were linked to a 15% lower risk of bone fractures in people with type 2 diabetes, according to research presented June 2026 at the Endocrine Society’s annual meeting. The study found semaglutide users had fewer fractures and greater weight loss compared with those taking other anti-obesity medications, suggesting potential bone-health benefits, officials said.
The study presented at the Endocrine Society’s annual meeting in Chicago in June 2026 reported that among people with type 2 diabetes, those taking semaglutide experienced 794 bone fractures compared with 1,045 fractures in a control group using other anti-obesity medications. This corresponds to a 15% lower fracture risk linked to semaglutide use, according to a press release from the Endocrine Society. The semaglutide group also showed a greater reduction in body mass index (BMI) than the comparator group, officials said.
Among people with type 2 diabetes, those taking semaglutide experienced 794 bone fractures compared with 1,045 fractures in a control group using other anti-obesity medications.
The research, presented as part of ENDO 2026, focused on fracture incidence rather than direct measures of bone mineral density or bone quality. Details about the study’s design were limited in the press release, and the findings do not establish causation but suggest a potential association between semaglutide use and reduced fracture risk relative to other weight-loss drugs, the society noted.
Additional studies provide a mixed picture of semaglutide’s effects on bone health. A retrospective cohort study published earlier in 2026 found that adults with obesity using semaglutide had a 26% lower fracture risk compared with those undergoing sleeve gastrectomy, with a hazard ratio of 0.74 and a 95% confidence interval of 0.56 to 0.98. The authors of that study described the result as indicating a possible bone-protective effect of semaglutide relative to surgical weight-loss treatments.
Conversely, a 2024 randomized trial involving adults at increased fracture risk found that semaglutide did not increase bone formation and was associated with higher bone resorption, a process that may be explained by weight loss, according to the study’s authors. That trial also reported decreases in lumbar spine and total hip areal bone mineral density after 52 weeks in the semaglutide group compared with placebo.
Weight loss itself is increasingly recognized as a factor that can compromise skeletal integrity. A 2025 review in Nature Reviews Endocrinology highlighted that rapid or sustained weight loss can reduce bone mineral density and increase fracture risk. Supporting this, a 2025 advance article in the Journal of Clinical Endocrinology & Metabolism (JCEM) reported that use of semaglutide or tirzepatide was associated with greater annualized total-hip bone loss in patients without diabetes. That study found a significant association between weight loss and bone loss at the total hip and femoral neck.
Further, a 2024-2025 Endocrine Society abstract documented significant declines in lumbar spine, femoral neck, and total hip bone mineral density among patients receiving semaglutide or tirzepatide, with total-hip decline linked to the amount of weight lost.
Not all research shows a fracture risk reduction with GLP-1 receptor agonists like semaglutide. A recent JCEM cohort study of older adults with type 2 diabetes reported an 11% increased fracture risk among new GLP-1 receptor agonist users compared with comparator therapies, with a hazard ratio of 1.11 and a 95% confidence interval of 1.01 to 1.21. In that study, GLP-1 receptor agonist use was associated with higher fracture risk than dipeptidyl peptidase-4 (DPP-4) inhibitors but not clearly higher than sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Another study in people with obesity but without diabetes found that GLP-1 receptor agonists were linked to increased fracture risk, with fracture incidence rates of 3.05% in exposed patients versus 2.61% in unexposed patients. That study also reported a stronger fracture risk signal in individuals with a body mass index over 40 and among older age groups.
The Endocrine Society’s June 2026 report compared semaglutide specifically with other anti-obesity medications rather than placebo. Prior research indicates that the effects of semaglutide and other GLP-1 receptor agonists on bone may vary depending on diabetes status, the amount of weight loss, and the comparator treatment used. Some data suggest that semaglutide may have a relatively favorable profile compared with bariatric surgery, which is known to negatively affect bone health. However, other datasets show either no clear bone benefit or a small increase in fracture risk, reflecting inconsistency in the literature.
The findings presented at ENDO 2026 add to a complex body of evidence regarding semaglutide’s impact on bone health. The reported 15% fracture risk reduction and fracture count differences provide important data points but do not confirm a protective effect on bone. Further research, including peer-reviewed studies with detailed methodology and longer follow-up, will be necessary to clarify semaglutide’s role in skeletal health among people with type 2 diabetes and obesity.
